ruxolitinib 25 MG Oral Tablet

Known as: RUXOLITINIB 25MG TAB,ORAL, RUXOLITINIB 25MG TAB,ORAL [VA Product], ruxolitinib (as ruxolitinib phosphate) 25 MG Oral Tablet 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2018
012320162018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2018
2018
OBJECTIVES To present the Central European Myeloproliferative Neoplasm Organisation (CEMPO) treatment recommendations for… (More)
Is this relevant?
2018
2018
STAT3 is constitutively activated in many cancers and regulates gene expression to promote cancer cell survival, proliferation… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Previously, we described an oncolytic vesicular stomatitis virus variant pseudotyped with the nonneurotropic glycoprotein of the… (More)
Is this relevant?
2016
2016
We determined whether the approved myelofibrosis drug ruxolitinib (Jakafi(®)), an inhibitor of Janus kinases 1/2 (JAK1 and JAK2… (More)
Is this relevant?